P. Pertile

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
P Pertile, P. Pertile, Paolo Pertile
Publication record
74 papers · 1,848 citations · H-index 18

PAPERS

The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysis.
20250 citationsauthor #3
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial
20214 citationsauthor #7
R&D and market size: Who benefits from orphan drug legislation?
20218 citationsauthor #3
A reply to "Who would benefit from average value-based pricing?"
20210 citationsauthor #2
Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”
20201 citationsauthor #2
The impact of managed entry agreements on pharmaceutical prices.
202031 citationsauthor #2
Which valued-based price when patients are heterogeneous?
202013 citationsauthor #2
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition
201917 citationsauthor #2
R&D and market size: who benefits from orphan drug regulation?
20191 citationsauthor #3
Drug price regulation in a nutshell : value based alternatives for personalised drugs in the presence of asymmetry of information
20190 citationsauthor #2
Job sick leave: Detecting opportunistic behavior
20183 citationsauthor #3
DD No . 18 / 04 FreeRiding in Pharmaceutical Price Regulation : Theory and Evidence
20180 citationsauthor #1
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence
20181 citationsauthor #1
Extracts of coprinus comatus and their use for regulating the pilosebaceous unit in a human
20180 citationsauthor #2
A Bayesian decision theoretic model of sequential experimentation with delayed response
201736 citationsauthor #3
Compliance to diagnostic and therapeutic pathways and innovative drug recommendations in advanced non-small cell lung cancer: preliminary results from the MOST study.
20170 citationsauthor #16
A large scale OLG model for the analysis of the redistributive effects of policy reforms
201715 citationsauthor #4
Ebola virus laboratory response: the three Dutch Mobile laboratories in Liberia and Sierra Leone
20165 citationsauthor #9
Redistribution at the local level: the case of public childcare in Italy
20163 citationsauthor #3
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation.
201617 citationsauthor #3
Pricing Policies When Patients are Heterogeneous: A Welfare Analysis
20165 citationsauthor #2
Intracrine sex steroid synthesis and signaling in human epidermal keratinocytes and dermal fibroblasts
201539 citationsauthor #3
Late-Stage Pharmaceutical R&D for Rare Diseases under Two-Stage Regulation
20151 citationsauthor #3
The fiscal disadvantage of young Italians: a new view on consolidation and fairness
20151 citationsauthor #1
Working Paper Series Department of Economics University of Verona Who should monitor job sick leave ?
20150 citationsauthor #3
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden
20153 citationsauthor #4
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy
201518 citationsauthor #1
Optimal sequential sampling with delayed observations and unknown variance
20154 citationsauthor #3
Therapeutic Value and Innovation of a Drug and Criteria for Evaluation: A Multidisciplinary Experience in the Veneto Region
20151 citationsauthor #16
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry
20155 citationsauthor #2
Who should monitor job sick leave
20152 citationsauthor #3
A large scale OLG model for France, Italy and Sweden: assessing the interpersonal and intrapersonal redistributive effects of public policies
20140 citationsauthor #4
The fiscal disadvantage of young Italians: a new view on consolidation and fairness
20140 citationsauthor #1
L'ISEE in Italia: una nota metodologica partendo dai dati EU-SILC. University of Verona Department of Economics Working Paper 6/2014 (ISSN 2036-2919)
20142 citationsauthor #5
EFFECTS OF DUPLEX-SPECIFIC NUCLEASE ON HUMAN CELLGENE EXPRESSION PROFILING USING RNA-SEQ
20140 citationsauthor #10
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies
201442 citationsauthor #1
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial.
201454 citationsauthor #5
Two-part payments for the reimbursement of investments in health technologies.
201414 citationsauthor #3
Ex vivo cultures on the basis of human sebaceous glands and their use as a screening tool
20130 citationsauthor #1
The dynamics of pharmaceutical regulation and R&D investments. WP Series University of Verona Department of Economics (ISSN 2036-2919), 4/2012
201319 citationsauthor #3
Redistribution at the Local Level: The Case of Public Childcare in Italy. University of Verona Department of Economics Working Paper 21/2013 (ISSN 2036-2919)
20130 citationsauthor #3
Public Health Interventions: Evaluating the Economic Evaluations
20131 citationsauthor #2
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
201316 citationsauthor #2
Working Paper Series Department of Economics University of Verona DRGs : the link between investment in technologies and appropriateness
20121 citationsauthor #3
Modelling Life-Course Decisions for the Analysis of Interpersonal and Intrapersonal Redistribution
20121 citationsauthor #3
Public Finance Consolidation and Fairness Across Living Generations: The Case of Italy
20120 citationsauthor #1
Dynamic, economic approaches to HTA under uncertainty. WP Series University of Verona Department of Economics (ISSN 2036-2919), 03/2011
20110 citationsauthor #2
Dynamic, economic approaches to HTA under uncertainty
20110 citationsauthor #2
Static and dynamic efficiency of irreversible health care investments under alternative payment rules.
201039 citationsauthor #3
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography
200921 citationsauthor #1
The timing of adoption of positron emission tomography: a real options approach
200912 citationsauthor #1
A Novel ex vivo Pig Skin Organ Culture Model for Efficacy and Safety Testing
20090 citationsauthor #4
A human folliculoid microsphere assay for exploring epithelial- mesenchymal interactions in the human hair follicle.
200977 citationsauthor #7
Investment in Health Technologies in a Competitive Model with Real Options
200810 citationsauthor #1
Expression patterns of the glial cell line-derived neurotrophic factor, neurturin, their cognate receptors GFRalpha-1, GFRalpha-2, and a common signal transduction element c-Ret in the human skin hair follicles.
200821 citationsauthor #3
A ‘hot’ new twist to hair biology – involvement of vanilloid receptor-1 signaling in human hair growth control
20085 citationsauthor #11
L‐Carnitine–L‐tartrate promotes human hair growth in vitro
200739 citationsauthor #4
Investment in Health Technologies: a Real Option Approach
20070 citationsauthor #1
Technology adoption, quality and health care costs: a review of the literature
20060 citationsauthor #1
Cross-Country Competition in Corporate Taxes
20060 citationsauthor #1
Control of human hair growth by neurotrophins: brain-derived neurotrophic factor inhibits hair shaft elongation, induces catagen, and stimulates follicular transforming growth factor beta2 expression.
200566 citationsauthor #5
THE CUTANEOUS VANILLOID RECEPTOR-1 (VR1) IS INVOLVED IN HUMAN HAIR GROWTH CONTROL
20040 citationsauthor #10
Reorganization of actin cytoskeleton by the phosphoinositide metabolite glycerophosphoinositol 4-phosphate.
200328 citationsauthor #6
ARF mediates recruitment of PtdIns-4-OH kinase-β and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex
1999560 citationsauthor #2
ADP-ribosylation factor regulates spectrin skeleton assembly on the Golgi complex by stimulating phosphatidylinositol 4,5-bisphosphate synthesis.
199914 citationsauthor #3
ADP ribosylation factor regulates spectrin binding to the Golgi complex.
1998130 citationsauthor #3
Molecular cloning, expression, and developmental characterization of the murine retinoblastoma-related gene Rb2/p130.
199525 citationsauthor #1
Phosphatidylinositol 4,5-Bisphosphate Synthesis Is Required for Activation of Phospholipase D in U937 Cells (*)
1995106 citationsauthor #1
Type 2 phosphatidylinositol 4-kinase is recruited to CD4 in response to CD4 cross-linking.
199514 citationsauthor #1
Mechanism underlying superantigen-induced clonal deletion of mature T lymphocytes.
199413 citationsauthor #3
Novel function of phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D.
1994271 citationsauthor #3
In vivo and in vitro Death of Mature T Cells Induced by Separate Signals to CD4 and αβTCR
199210 citationsauthor #3
Apoptosis of Mature T Lymphocytes
19921 citationsauthor #4
In vivo and in vitro death of mature T cells induced by separate signals to CD4 and alpha beta TCR.
19922 citationsauthor #3

TIMELINE

1992 13 citations

1994 284 citations

1995 145 citations

1998 130 citations

1999 574 citations

2003 28 citations

2004 0 citations

2005 66 citations

2006 0 citations

2007 39 citations

2008 36 citations

2009 110 citations

2010 39 citations

2011 0 citations

2012 2 citations

2013 36 citations

2014 112 citations

2015 74 citations

2016 30 citations

2017 51 citations

2018 4 citations

2019 18 citations

2020 45 citations

2021 12 citations

2025 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT